drugset
drugset / Trial / NCT04612062

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062 ↗

Phase 1 Completed 28 enrolled Novartis Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

Timeline

Start
2020-02-27
Primary completion
2021-05-16
Completion
2021-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CEE321 Unknown 0.2 % Topical

Indications

atopic eczema